Form 4: Haemonetics Corp Director Lloyd Emerson Johnson Reports Acquisition of Restricted Stock Units

Director Lloyd Emerson Johnson reports acquiring 2,207 restricted stock units of Haemonetics Corp on July 25, 2024.

Summary

• On July 25, 2024, Lloyd Emerson Johnson, a director of Haemonetics Corp, acquired 2,207 restricted stock units (RSUs).
• These RSUs were issued under the company's Amended and Restated 2019 Long-Term Incentive Compensation Plan.
• The RSUs vest 100% on the first anniversary of the grant date.
• Each RSU represents the contingent right to receive one share of Haemonetics Corp's common stock upon vesting.
• Following the transaction, Johnson beneficially owns 10,240 shares of common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing indicating insider activity. The acquisition of RSUs is generally a positive sign, but it's a routine occurrence.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The RSUs vest 100% on the first anniversary of the grant date, indicating a future event tied to continued service or performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be indicative of their confidence in the company's prospects.

Stakeholder Impact

• The acquisition of RSUs by a director can positively influence shareholder sentiment.

Key Dates